38 results about "Mrna transfection" patented technology

The invention discloses a DC cell based on SP17 antigen, a targeting immune cell population, a preparation method and applications thereof. The preparation method of DC cell comprises the following steps: subjecting mononuclear cells to first induced differentiation culture to obtain immature DC cells; transfecting the immature DC cells by SP17 antigen mRNA to obtain transfected immature DC cells; subjecting the transfected immature DC cell to second induced differentiation culture to obtain mature DC cells; wherein the mononuclear cells are separated from peripheral blood mononuclear cells of a sample. Through the provided preparation method, DC cells can be obtained efficiently and safely. Moreover, the provided preparation method has the advantages of low cost and high efficiency, and can effectively solve the problem of cell toxicity. The DC cells can be applied to cell immunotherapy or used to trigger the lymph cells from the same patient to generate targeting immune cell population rich in CTL cells so as to achieve a better effect in tumor immunotherapy.

A method is provided for treating or preventing an undesired immune response in a patient, comprising: administering to said patient, cells that transiently express, and / or that are transfected with mRNA encoding, one or more polypeptides selected from the group consisting of an IL-4 receptor agonist, an IFN-γ receptor antagonist, an IFN-α receptor antagonist, an IL-12 receptor antagonist, an IL-23 receptor antagonist, and a TNF antagonist. Preferably, the cells selectively accumulate in one or more secondary lymphoid tissues at or proximate to the site of the undesired immune response. Related compositions are provided. The methods and compositions are useful for the treatment or prevention of undesired immune responses including, but not limited to, transplant rejection, autoimmune disease, allergy and immune responses directed against therapeutic compositions.

The invention discloses a culture medium, a kit and application for in-vitro chondrocyte telomere multiplication culture. The culture medium is prepared by adding serum, vitamin C having a final concentration of 5-50mu g / ml, B18R or p65i having a final concentration of 0.01-2mu g / ml, rapamycin having a final concentration of 0.1-50ng / ml and resveratrol having a final concentration of 0.1-50mu M into a DMEM / F12 or RPMI1640 basic culture medium, wherein the serum is human AB serum having a volume final concentration of 1-20 percent or fetal calf serum having a volume final concentration of 1-20 percent. By using the culture medium or kit for in-vitro chondrocyte telomere multiplication culture, chondrocyte can be subjected to telomerase mRNA transfection in vitro, so that telomere of chondrocyte is lengthened in subsequent culturing, and multiplication and vitality of chondrocyte, especially senile patients, can be remarkably improved. The culture medium or kit can be used for improving or treating cell function decline caused by senescence, and can be practically applied to regenerative medicine treatment.

The invention discloses a DC cell based on BCG1 antigen, a targeting immune cell population, a preparation method and applications thereof. The preparation method of DC cell comprises the following steps: subjecting mononuclear cells to first induced differentiation culture to obtain immature DC cells; transfecting the immature DC cells by BCG1 antigen mRNA to obtain transfected immature DC cells; subjecting the transfected immature DC cell to second induced differentiation culture to obtain mature DC cells; wherein the mononuclear cells are separated from peripheral blood mononuclear cells of a sample. Through the provided preparation method, DC cells can be obtained efficiently and safely. Moreover, the provided preparation method has the advantages of low cost and high efficiency, and can effectively solve the problem of cell toxicity. The DC cells can be applied to cell immunotherapy or used to trigger the lymph cells from the same patient to generate targeting immune cell population rich in CTL cells so as to achieve a better effect in tumor immunotherapy.

The invention discloses a DC cell based on P53 antigen, a targeting immune cell population, a preparation method and applications thereof. The preparation method of DC cell comprises the following steps: subjecting mononuclear cells to first induced differentiation culture to obtain immature DC cells; transfecting the immature DC cells by P53 antigen mRNA to obtain transfected immature DC cells; subjecting the transfected immature DC cell to second induced differentiation culture to obtain mature DC cells; wherein the mononuclear cells are separated from peripheral blood mononuclear cells of a sample. Through the provided preparation method, DC cells can be obtained efficiently and safely. Moreover, the provided preparation method has the advantages of low cost and high efficiency, and can effectively solve the problem of cell toxicity. The DC cells can be applied to cell immunotherapy or used to trigger the lymph cells from the same patient to generate targeting immune cell population rich in CTL cells so as to achieve a better effect in tumor immunotherapy.

The present invention relates to a method of differentiating neural stem cells or neural precursor cells into dopamine neurons and more particularly, a method of differentiating into dopamine neurons, in which chromosomal stability is maintained by transfecting neural stem cells or neural precursor cells with mRNA of a dopamine neuron-inducing transcription factor under time-based control. The method of differentiating into dopamine neurons, according to the present invention, may enable preparation of mature and functional dopamine neurons having chromosomal stability by synthesizing a dopamine neuron-inducing transcription factor into a mRNA form, which has no risk of genetic modification, and transfecting the synthetic mRNA, unlike existing methods using retroviral vectors, and thus may be usefully used in the clinical field for the treatment of Parkinson's disease.

The invention discloses a culture medium, a kit and application for in-vitro chondrocyte telomere multiplication culture. The culture medium is prepared by adding serum, vitamin C having a final concentration of 5-50mu g / ml, B18R or p65i having a final concentration of 0.01-2mu g / ml, rapamycin having a final concentration of 0.1-50ng / ml and resveratrol having a final concentration of 0.1-50mu M into a DMEM / F12 or RPMI1640 basic culture medium, wherein the serum is human AB serum having a volume final concentration of 1-20 percent or fetal calf serum having a volume final concentration of 1-20 percent. By using the culture medium or kit for in-vitro chondrocyte telomere multiplication culture, chondrocyte can be subjected to telomerase mRNA transfection in vitro, so that telomere of chondrocyte is lengthened in subsequent culturing, and multiplication and vitality of chondrocyte, especially senile patients, can be remarkably improved. The culture medium or kit can be used for improving or treating cell function decline caused by senescence, and can be practically applied to regenerative medicine treatment.

The invention discloses a DC cell based on SCC antigen, a targeting immune cell population, a preparation method and applications thereof. The preparation method of DC cell comprises the following steps: subjecting mononuclear cells to first induced differentiation culture to obtain immature DC cells; transfecting the immature DC cells by SCC antigen mRNA to obtain transfected immature DC cells; subjecting the transfected immature DC cell to second induced differentiation culture to obtain mature DC cells; wherein the mononuclear cells are separated from peripheral blood mononuclear cells of a sample. Through the provided preparation method, DC cells can be obtained efficiently and safely. Moreover, the provided preparation method has the advantages of low cost and high efficiency, and can effectively solve the problem of cell toxicity. The DC cells can be applied to cell immunotherapy or used to trigger the lymph cells from the same patient to generate targeting immune cell population rich in CTL cells so as to achieve a better effect in tumor immunotherapy.

The invention discloses a method for lengthening, proliferating and culturing in-vitro telomeres of cartilage cells and human tissue engineering regenerated cartilage. The method and the human tissue engineering regenerated cartilage have the advantages that telomerase mRNA [(messenger RNA (ribonucleic acid)) transfection is carried out on the cartilage cells in an in-vitro manner, accordingly, the telomeres in cartilage cells obtained by means of culturing in follow-up procedures can be lengthened, proliferation and the viability of the cartilage cells and cartilage cells of elderly patients in particular can be obviously improved by the aid of synergistic effects of the telomerase mRNA transfection and small molecule compounds such as vitamin C, B18R or p65i, rapamycin and resveratrol in complete media, and the method and the human tissue engineering regenerated cartilage have important significance in improving or treating cell function decline due to senescence when the actually applied to regeneration medical treatment; the telomeres of the cartilage cells are not continuously or even frequently lengthened by the aid of the method for lengthening, proliferating and culturing the in-vitro telomeres of the cartilage cells, accordingly, genome insertion mutation risks or cell immortalization tumor formation risks can be prevented, the safety and the applicability can be greatly improved, and the method and the human tissue engineering regenerated cartilage can be effectively applied to the regeneration medical treatment.